HK1223285A1 - 包含具有减小的免疫原性的经修饰的噬菌体g3p氨基酸序列的多肽 - Google Patents

包含具有减小的免疫原性的经修饰的噬菌体g3p氨基酸序列的多肽 Download PDF

Info

Publication number
HK1223285A1
HK1223285A1 HK16111571.6A HK16111571A HK1223285A1 HK 1223285 A1 HK1223285 A1 HK 1223285A1 HK 16111571 A HK16111571 A HK 16111571A HK 1223285 A1 HK1223285 A1 HK 1223285A1
Authority
HK
Hong Kong
Prior art keywords
polypeptides
amino acid
acid sequence
reduced immunogenicity
modified bacteriophage
Prior art date
Application number
HK16111571.6A
Other languages
English (en)
Chinese (zh)
Inventor
Francis Joseph Carr
Timothy David Jones
Richard A. Fisher
Robert George Edward Holgate
Original Assignee
Proclara Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proclara Biosciences, Inc. filed Critical Proclara Biosciences, Inc.
Publication of HK1223285A1 publication Critical patent/HK1223285A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
HK16111571.6A 2013-05-28 2014-05-28 包含具有减小的免疫原性的经修饰的噬菌体g3p氨基酸序列的多肽 HK1223285A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361828004P 2013-05-28 2013-05-28
US201361828004P 2013-05-28
US201361828497P 2013-05-29 2013-05-29
US201361828497P 2013-05-29
PCT/US2014/039760 WO2014193935A1 (en) 2013-05-28 2014-05-28 Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity

Publications (1)

Publication Number Publication Date
HK1223285A1 true HK1223285A1 (zh) 2017-07-28

Family

ID=51168338

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16111571.6A HK1223285A1 (zh) 2013-05-28 2014-05-28 包含具有减小的免疫原性的经修饰的噬菌体g3p氨基酸序列的多肽

Country Status (13)

Country Link
US (2) US9988444B2 (enExample)
EP (1) EP3003349B1 (enExample)
JP (1) JP2016526044A (enExample)
KR (1) KR20160010618A (enExample)
CN (1) CN105473153A (enExample)
AU (1) AU2014274253B2 (enExample)
CA (1) CA2913414A1 (enExample)
EA (1) EA030389B1 (enExample)
HK (1) HK1223285A1 (enExample)
MX (1) MX2015016263A (enExample)
PH (1) PH12015502585A1 (enExample)
SG (1) SG11201509647WA (enExample)
WO (1) WO2014193935A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2785364B1 (en) 2011-11-29 2019-01-09 Proclara Biosciences, Inc. Use of p3 of bacteriophage as amyloid binding agents
MX358755B (es) 2012-10-02 2018-09-03 Proclara Biosciences Inc Uso del p3 de proteinas de fusion de bacteriofago como agentes de union amiloides.
SG11201704427YA (en) * 2014-12-03 2017-06-29 Proclara Biosciences Inc Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal
CN107384960B (zh) * 2017-07-25 2020-06-12 吉优诺（上海）基因科技有限公司 基于复制缺陷性重组腺病毒携带il-17结合分子转基因载体及其构建方法和应用
US11692017B2 (en) 2018-06-15 2023-07-04 Amyl Therapeutics Srl General amyloid interaction motif (GAIM)
EP3966227A1 (en) 2019-05-07 2022-03-16 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
BR112023001238A2 (pt) 2020-07-24 2023-04-04 Jawaharlal Nehru Centre For Advanced Scient Research Compostos de monoimida de naftaleno e métodos para os mesmos
CN114057858B (zh) * 2020-08-10 2023-03-21 上海瑞吉康生物医药有限公司 对引起神经变性和神经退行性疾病的蛋白聚集具有解聚作用的多肽
KR20250110352A (ko) 2022-12-02 2025-07-18 알제온, 인크. 트라미프로세이트를 이용하여 신경퇴행성 장애를 치료하는 방법

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
ES2199935T3 (es) 1991-03-15 2004-03-01 Amgen Inc. Pegilacion de polipeptidos.
JP3068301B2 (ja) * 1992-01-08 2000-07-24 三菱電機株式会社 Ｉｃカード内のコネクタ支持固定機構
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO1993024135A1 (en) 1992-05-26 1993-12-09 Immunex Corporation Novel cytokine that binds cd30
ES2258817T3 (es) 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
US8022270B2 (en) 2000-07-31 2011-09-20 Biolex Therapeutics, Inc. Expression of biologically active polypeptides in duckweed
AU2002233340B2 (en) 2001-02-19 2008-05-22 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
KR20030082962A (ko) 2001-03-08 2003-10-23 메르크 파텐트 게엠베하 감소된 면역원성을 갖는 개질된과립구대식세포집락자극인자(ｇｍ-ｃｓｆ)
DE10238846A1 (de) 2002-08-20 2004-03-04 Nemod Immuntherapie Ag Aktive Fusionsproteine und Verfahren zu ihrer Herstellung
JP5096169B2 (ja) 2005-02-01 2012-12-12 ラモット・アット・テルアビブ・ユニバーシティ アミロイド沈着に付随する炎症および活性化されたマイクログリアにかかわる脳の炎症の処置法
AU2007214399A1 (en) 2006-02-15 2007-08-23 Ramot At Tel-Aviv University Filamentous bacteriophage displaying protein as a binder of antibodies and immunocomplexes for delivery to the brain
WO2007094003A2 (en) 2006-02-15 2007-08-23 Ramot At Tel Aviv University Ltd. Viral display vehicles for treating multiple sclerosis
WO2007109733A2 (en) 2006-03-21 2007-09-27 The Johns Hopkins University Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
US20090105090A1 (en) 2006-04-06 2009-04-23 Fumiaki Uchiyama Phage Display By Novel Filamentous Bacteriophage
CN101553567A (zh) 2006-07-21 2009-10-07 台拉维夫大学拉莫特 抑制或治疗与细胞内形成蛋白纤维状内含体或聚集体相关的疾病的方法
KR101485202B1 (ko) 2006-10-11 2015-01-22 안티토페 리미티드 Ｔ 세포 에피토프 데이터베이스들
WO2009143470A1 (en) 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Method for treating disease characterized by plaque
AU2009316326A1 (en) 2008-11-24 2010-05-27 Ramot At Tel-Aviv University Ltd. Method for treating Parkinson' s disease using filamentous bacteriophage
WO2011084714A2 (en) * 2009-12-17 2011-07-14 Biogen Idec Ma Inc. STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
JP2014509514A (ja) 2011-03-11 2014-04-21 ラモット アット テルアヴィブ ユニヴァーシティ リミテッド 神経変性タウオパシーを治療するための方法
EP2785364B1 (en) 2011-11-29 2019-01-09 Proclara Biosciences, Inc. Use of p3 of bacteriophage as amyloid binding agents
MX358755B (es) * 2012-10-02 2018-09-03 Proclara Biosciences Inc Uso del p3 de proteinas de fusion de bacteriofago como agentes de union amiloides.
SG11201704427YA (en) 2014-12-03 2017-06-29 Proclara Biosciences Inc Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal

Also Published As

Publication number Publication date
US20160115223A1 (en) 2016-04-28
AU2014274253A1 (en) 2016-01-21
JP2016526044A (ja) 2016-09-01
EP3003349B1 (en) 2018-12-12
US9988444B2 (en) 2018-06-05
CA2913414A1 (en) 2014-12-04
EP3003349A1 (en) 2016-04-13
EA201592272A1 (ru) 2016-04-29
AU2014274253B2 (en) 2018-06-14
US20170129945A9 (en) 2017-05-11
CN105473153A (zh) 2016-04-06
MX2015016263A (es) 2016-04-18
WO2014193935A1 (en) 2014-12-04
KR20160010618A (ko) 2016-01-27
PH12015502585A1 (en) 2016-02-29
SG11201509647WA (en) 2015-12-30
US20180251534A1 (en) 2018-09-06
EA030389B1 (ru) 2018-07-31

Similar Documents

Publication Publication Date Title
HK1223285A1 (zh) 包含具有减小的免疫原性的经修饰的噬菌体g3p氨基酸序列的多肽
PH12017501004A1 (en) Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal
CA2856891C (en) Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
SA518390954B1 (ar) لقاحات علاجية لفيروس الورم الحليمي البشري 18
MX2014009909A (es) Acido nucleico que comprende o codifica un tallo-bucle de histona y una secuencia poli(a) o una señal de poliadenilacion para incrementar la expresion de un antigeno tumoral codificado.
MX359953B (es) Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada.
MY196882A (en) Recombinant binding proteins and their use
WO2015048348A3 (en) Compositions and formulations for increasing renal function and treatment and prevention of renal diseases, and methods of production and use thereof
WO2013040093A3 (en) Glucagon-like peptide-2 compositions and methods of making and using same
WO2016005466A3 (en) IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES
WO2014150600A3 (en) Modified toxins
WO2014204816A3 (en) Method for assessing protein identity and stability
NZ703597A (en) Mutant fragments of ospa and methods and uses relating thereto
NZ721015A (en) Mutant fragments of ospa and methods and uses relating thereto
PH12017500450A1 (en) Flavivirus virus like particle
MX2014004953A (es) Ligadores basados en tirosina para la conexion desprendible de peptidos.
MX2019003970A (es) Péptidos de arginasa inmunogénicos.
HK1252350A1 (zh) Mrka多肽、抗体及其用途
WO2016007919A3 (en) Antibody fragments for detecting cancer and methods of use
WO2016075305A3 (en) Peptides derived from acinetobacter baumannii and their use in vaccination
IL287987A (en) Improved dried formulations relating to hyaluronic acid and plasmatic proteins, and their uses
MX358118B (es) Vacuna contra el virus de la leucemia bovina.
WO2015132103A3 (en) Polypeptides derived from enterococcus and their use for vaccination and the generation of therapeutic antibodies
HK1232900A1 (en) IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES
WO2017005615A3 (en) Antigenic peptides for the diagnosis, therapy monitoring and/or treatment of psoriasis vulgaris